<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3200">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667936</url>
  </required_header>
  <id_info>
    <org_study_id>#20-643 -Sed II</org_study_id>
    <nct_id>NCT04667936</nct_id>
  </id_info>
  <brief_title>Evaluation of Sedation in COVID-19 ARDS</brief_title>
  <official_title>Evaluation of Impaired Sedation in Patients With Moderate to Severe COVID-19 ARDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goethe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focuses on the evaluation of various factors repeatedly discussed in relation to&#xD;
      the impaired sedation of intubated ventilated COVID-19 patients. The sedation response of&#xD;
      &gt;100 moderately to severely affected COVID-19 ARDS was evaluated. The sedation level was&#xD;
      measured at the bedside using the Richmond Agitation and Sedation Scale and ventilator&#xD;
      synchrony. The evaluation was performed according to the static evaluation plan with respect&#xD;
      to age, storage therapy and organ failure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Position therapy</measure>
    <time_frame>Data collection is performed at the date of death from any cause or discharge up to 10 weeks.</time_frame>
    <description>Number of positioning therapys during treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agitation and sedation level</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Measurement is performed using the Richmond Agitation and Sedation Scale (RASS, range: -5[Unarousable] to +4 [Combative], normal condition=0 [Alert and calm])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Agitation and sedation level</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Change of sedation level using the Richmond Agitation and Sedation Scale (RASS, range: -5[Unarousable] to +4 [Combative], normal condition=0 [Alert and calm])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of opioid analgesic</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of sufentanil (measured in µg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of application of opioid analgesic</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of sufentanil (measured in µg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of opioid analgesic</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of remifentanil (measured in µg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of application of opioid analgesic</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of remifentanil (measured in µg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of sedative</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of midazolam (measured in mg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sedative dosage applied</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of midazolam (measured in mg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of sedative</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of propofol (measured in mg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sedative dosage applied</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of propofol (measured in mg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of sedative</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of lormetazepam (measured in mg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sedative dosage applied</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of lormetazepam (measured in mg/kg/min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of sedative</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of clonidine (measured in µg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sedative dosage applied</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of clonidine (measured in µg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of sedative</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of Dexmethomidine (measured in µg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sedative dosage applied</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of Dexmethomidine (measured in µg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Application of sedative</measure>
    <time_frame>30 minutes after study enrolment</time_frame>
    <description>Applied dosage of esketamine (measured in mg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sedative dosage applied</measure>
    <time_frame>Change in average dosage within 8 hours.</time_frame>
    <description>Applied dosage of esketamine (measured in mg/kg/h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Characteristics</measure>
    <time_frame>The data is recorded at the time of enrolment</time_frame>
    <description>Age (in years)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Characteristics</measure>
    <time_frame>The data is recorded at the time of enrolment</time_frame>
    <description>Height (in centimeters)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Characteristics</measure>
    <time_frame>The data is recorded at the time of enrolment</time_frame>
    <description>Weight (in kilograms)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>Data collection is performed at the date of death from any cause or discharge up to 10 weeks.</time_frame>
    <description>The necessity and application of a renal replacement procedure is documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for extracorporeal membrane oxygenation (vvECMO)</measure>
    <time_frame>Data collection is performed at the date of death from any cause or discharge up to 10 weeks.</time_frame>
    <description>The necessity and application of an extracorporeal oxygenation procedure (ECMO) is documented</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prone Position</condition>
  <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
  <condition>Hypnotics and Sedatives</condition>
  <condition>Pulmonary Ventilation</condition>
  <arm_group>
    <arm_group_label>moderate to severe COVID-19 ARDS</arm_group_label>
    <description>patients with an oxygenation index &lt;200 under intubation anesthesia and mechanical ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment group</intervention_name>
    <description>None, solely treatment documentation</description>
    <arm_group_label>moderate to severe COVID-19 ARDS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients admitted to the intensive care unit who were already diagnosed with&#xD;
        (SARS-CoV-2) infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        moderate to severe COVID-19 ARDS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin N Flinspach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armin N Flinspach, MD</last_name>
    <phone>+49 69-6301</phone>
    <phone_ext>5868</phone_ext>
    <email>armin.flinspach@kgu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth H Adam, MD</last_name>
    <phone>+49 69-6301</phone>
    <phone_ext>5868</phone_ext>
    <email>elisabeth.adam@kgu.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin N Flinspach, MD</last_name>
      <phone>+49 69 6301 5868</phone>
      <email>armin.flinspach@kgu.de</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth H Adam, MD</last_name>
      <phone>+49 69 6301 5868</phone>
      <email>elisabeth.adam@kgu.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 12, 2020</last_update_submitted>
  <last_update_submitted_qc>December 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Elisabeth H. Adam</investigator_full_name>
    <investigator_title>Senior Physician</investigator_title>
  </responsible_party>
  <keyword>Critical Care</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

